Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402493 | 1.00 | MAPK1 (0.56) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL22119231 | 0.87 | MAPK1 (0.56) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL749735 | 0.86 | CYP1A2 (0.45) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL29550528 | 0.86 | MAPK1 (0.54) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL20423622 | 0.86 | MAPK1 (0.54) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL23530000 | 0.86 | MAPK1 (0.54) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL1173618 | 0.86 | MAPK1 (0.54) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL11375152 | 0.86 | MAPK1 (0.54) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL13466852 | 0.85 | MAPK1 (0.57) | MAPK1MAPTRAB9AKDM4EL3MBTL1 | |
| SCHEMBL30402265 | 0.85 | MAPK1 (0.57) | MAPK1MAPTRAB9AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20120302558-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-11-29 | — | — | US | disclosed |
| US-20120238560-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | MAPK1 1219/4885MAPT 8/4885RAB9A 1100/4885 |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | MAPK1 2893/4885MAPT 3705/4885RAB9A 4055/4885 |
| US-20120302558-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | MAPK1 2538/4885MAPT 45/4885RAB9A 4204/4885 |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | MAPK1 2538/4885MAPT 45/4885RAB9A 4204/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MAPK1 2422/4885MAPT 4245/4885RAB9A 3820/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | MAPK1 2538/4885MAPT 45/4885RAB9A 4204/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | MAPK1 1219/4885MAPT 8/4885RAB9A 1100/4885 |
| US-20120238560-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | MAPK1 2538/4885MAPT 45/4885RAB9A 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.